Page 3 - Ganx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ganx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ganx Today - Breaking & Trending Today

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Increases By 20.2%

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 60,000 shares, a growth of 20.2% from the March 15th total of 49,900 shares. Approximately 0.7% of the shares of the company are short sold. Based on […] ....

Gain Therapeutics Inc , Dimensional Fund Advisors , Royal Bank , Raymond James Associates , Gain Therapeutics Company Profile , Renaissance Technologies , Gain Therapeutics , Get Rating , Chardan Capital , Fund Advisors , Jane Street Group , Site Directed Enzyme Enhancement Therapy , Gain Therapeutics Daily , Nasdaq Ganx ,

Chardan Capital Raises Gain Therapeutics (NASDAQ:GANX) Price Target to $5.75

Gain Therapeutics (NASDAQ:GANX – Get Rating) had its price target boosted by Chardan Capital from $4.00 to $5.75 in a research report released on Monday, The Fly reports. Gain Therapeutics Stock Up 3.0 % GANX opened at $4.82 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.11 and a […] ....

Gain Therapeutics Inc , Raymond James Associates , Dimensional Fund Advisors , Renaissance Technologies , Wealth Alliance Advisory Group , Gain Therapeutics Company Profile , Gain Therapeutics , Get Rating , Chardan Capital , Fund Advisors , Alliance Advisory Group , Jane Street Group , Site Directed Enzyme Enhancement Therapy , Gain Therapeutics Daily , Nasdaq Ganx , Boost Price Target ,

Gain Therapeutics (NASDAQ:GANX) Upgraded at Zacks Investment Research

Gain Therapeutics (NASDAQ:GANX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 3.77% from the stock’s previous […] ....

Gain Therapeutics Inc , Zacks Investment Research , Cm Management , Millennium Management , Royal Bank , Gain Therapeutics , Get Rating , Investment Research , Site Directed Enzyme Enhancement Therapy , Nasdaq Ganx ,

Gain Therapeutics, Inc. (NASDAQ:GANX) CEO Eric I. Richman Buys 4,000 Shares

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) CEO Eric I. Richman acquired 4,000 shares of the business’s stock in a transaction on Thursday, May 19th. The shares were purchased at an average cost of $2.71 per share, for a total transaction of $10,840.00. Following the completion of the acquisition, the chief executive officer now directly […] ....

Erici Richman , Gain Therapeutics Inc , Securities Exchange Commission , Advisor Group Holdings Inc , Zacks Investment Research , Citadel Advisors , Millennium Management , Gain Therapeutics , Get Rating , Exchange Commission , Street Group , Group Holdings , Site Directed Enzyme Enhancement Therapy , Nasdaq Ganx , Insider Trading , Nsider Trades ,

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Drops By 17.9%

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 30,800 shares, a decline of 17.9% from the February 28th total of 37,500 shares. Approximately 0.4% of the shares of the company are sold […] ....

Gain Therapeutics Inc , Indie Asset Partners , Zacks Investment Research , Cm Management , Millennium Management , Gain Therapeutics , Get Rating , Asset Partners , Site Directed Enzyme Enhancement Therapy , Nasdaq Ganx ,